Trendy apparel company Lot78 Inc. (OTC Limited Info: LOTE) says it will expand the marketing of its upscale product line by using a $984,000 credit line it received from a new factoring agreement.
Breaking months of silence, this sudden announcement from the UK-based Lot 78 has ignited its stock volume which soared to 1,067,410 shares Jan. 16, 2014. This is substantially higher than its three-month daily average of 314,605. The company’s stock has been on a rollercoaster ride with a 52-week high of $6.25 cents to a 52-week low of 4 cents.
But at least it’s clear that Lot 78 has come out its self-imposed public-relations exile when it made a second positive announcement to its stockholders on Jan. 16, 2014. The company will be rolling out its product line this summer in the upscale Harvey Nichols boutiques.
This could be a pretty big deal because Harvey Nichols, founded in 1831, currently has stores in London, Leeds, Birmingham, Edinburgh, Manchester and Bristol in the UK, Dublin in the Republic of Ireland and internationally Riyadh, Hong Kong, Dubai, Turkey and Kuwait. Lot 78 hopes this rollout will significantly boost the sales of its men’s and women's contemporary ready-to-wear line that includes leather jackets, coats, knitwear, jeans, chinos, t-shirts, sweats and accessories.
During midday trading Jan. 17, LOTE share price was trading at 0.0837 cents, down 8.02 % from its closing share price of 0.091cents the previous day.
Find out what could be the best investor’s move when it comes to LOTE by getting the complete report here, or by cutting and pasting the following link in your Web browser:
San Francisco-based Amarantus BioScience, Inc. (OTCQB: AMBS) stock volume is also skyrocketing, with 10,953,702 shares changing hands Jan. 16, more than doubling its three-month daily average share volume of 5,211,361.
This volume comes on the heels of news the biotech company that’s developing treatments for such neurodegenerative diseases as Parkinson’s and Alzheimer’s has been granted worldwide rights to Eltoprazine. This is a new drug that treats Parkinson’s disease and recently went through Phase2 trials during which it was given to 700 patients.
“Eltoprazine is the most advanced drug candidate in this class. Adequately addressing LID in Parkinson's disease would represent a significant improvement to the standard of care for patients worldwide and is a significant commercial opportunity,” Amarantus Board of Directors David A. Lowe said in a written statement.
During midday trading Jan. 17, AMBS share price was trading at 0.086 cents, down 2.06 % from its closing share price of 0.0883 cents the previous day.
Find out what could be the best investor’s move when it comes to AMBS by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Sixfigurestockpicks.com is often in the know of several large investor awareness campaigns being deployed.Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.Simply sign up for free and start receiving exclusive alerts.Subscribe Here: http://http://www.sixfigurestockpicks.com/